Current and emerging treatments for the management of osteogenesis imperfecta

Elena Monti, Monica Mottes, Paolo Fraschini, Piercarlo Brunelli, Antonella Forlino, Giacomo Venturi, Francesco Doro, Silvia Perlini, Paolo Cavarzere, Franco Antoniazzi, Elena Monti, Monica Mottes, Paolo Fraschini, Piercarlo Brunelli, Antonella Forlino, Giacomo Venturi, Francesco Doro, Silvia Perlini, Paolo Cavarzere, Franco Antoniazzi

Abstract

Osteogenesis imperfecta (OI) is the most common bone genetic disorder and it is characterized by bone brittleness and various degrees of growth disorder. Clinical severity varies widely; nowadays eight types are distinguished and two new forms have been recently described although not yet classified. The approach to such a variable and heterogeneous disease should be global and therefore multidisciplinary. For simplicity, the objectives of treatment can be reduced to three typical situations: the lethal perinatal form (type II), in which the problem is survival at birth; the severe and moderate forms (types III-IX), in which the objective is 'autonomy'; and the mild form (type I), in which the aim is to reach 'normal life'. Three types of treatment are available: non-surgical management (physical therapy, rehabilitation, bracing and splinting), surgical management (intramedullary rod positioning, spinal and basilar impression surgery) and medical-pharmacological management (drugs to increase the strength of bone and decrease the number of fractures as bisphosphonates or growth hormone, depending on the type of OI). Suggestions and guidelines for a therapeutic approach are indicated and updated with the most recent findings in OI diagnosis and treatment.

Keywords: adult onset deafness; blue sclerae; bone brittleness; bone genetic disorder; connective tissue malfunction; dentinogenesis imperfecta; joint laxity; osteogenesis imperfecta; progressive skeletal deformities; short stature; “brittle bone disease”.

References

    1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377–1385.
    1. Cheung MS, Glorieux FH. Osteogenesis Imperfecta: update on presentation and management. Rev Endocr Metab Disord. 2008;9:153–160.
    1. Marini JC, Cabral WA, Barnes AM. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell Tissue Res. 2010;339(1):59–70.
    1. Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res. 2009;9999(999A):1–30.
    1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–16.
    1. van Dijk FS, Pals G, van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53(1):1–5.
    1. Barnes AM, Carter EM, Cabral WA, et al. Lack of cyclophilin b in osteogenesis imperfecta with normal collagen folding. N Engl J Med. 2010;362:521–528.
    1. Byers PH, Krakow D, Nunes ME, Pepin M. Genetic evaluation of suspected osteogenesis imperfecta (OI) Genet Med. 2006;8:383–388.
    1. Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat. 2007;28:209–221.
    1. Venturi G, Tedeschi E, Mottes M, et al. Osteogenesis imperfecta: clinical, biochemical and molecular findings. Clin Genet. 2006;70:131–139.
    1. Barnes AM, Chang W, Morello R, et al. Deficiency of cartilage – associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med. 2006;355:2757–2764.
    1. Morello R, Bertin TK, Chen Y, et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006;127:291–304.
    1. Baldridge D, Schwarze U, Morello R, et al. CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat. 2008;29:1435–1442.
    1. Willaert A, Malfait F, Symoens S, et al. Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl-3-hydroxylation. J Med Genet. 2009;46:233–241.
    1. van Dijk FS, Nesbitt IM, Zwikstra EH, et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet. 2009;85:521–527.
    1. Christiansen HE, Schwarze U, Pyott SM, et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive Osteogenesis Imperfecta. Am J Hum Genet. 2010;86:389–398.
    1. Antoniazzi F, Mottes M, Fraschini P, Brunelli PC, Tato L. Osteogenesis imperfecta: practical treatment guidelines. Paediatr Drugs. 2000;2:465–488.
    1. Rauch F, Glorieux FH. Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet C Semin Med Genet. 2005;139C:31–37.
    1. Glorieux FH. Treatment of osteogenesis imperfecta: who, why, what. Horm Res. 2007;68:8–11.
    1. Miller ME, Hangartner TN. Temporary brittle bone disease: association with decreased fetal movement and osteopenia. Calcif Tissue Int. 1999;64:137–143.
    1. Smith R. Osteogenesis imperfecta, non – accidental injury, and temporary brittle bone disease. Arch Dis Child. 1995;72:169–171.
    1. Moore MS, Minch CM, Kruse RW, Harcke HT, Jacobson L, Taylor A. The role of dual energy x-ray absorptiometry in aiding the diagnosis of pediatric osteogenesis imperfecta. Am J Orthop. 1998;27:797–780.
    1. Davie MWJ, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child. 1994;70:331–334.
    1. Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. 2008;42:456–466.
    1. Steiner RD, Pepin M, Byers PH. Studies of collagen synthesis and structure in the differentiation of child abuse from osteogenesis imperfecta. J Pediatr. 1996;128:542–547.
    1. van Brussel M, Takken T, Uiterwaal CS, et al. Physical training in children with osteogenesis imperfecta. J Pediatr. 2008;152:111–116.
    1. Smith R, Phillips AJ. Osteoporosis during pregnancy and its management. Scand J Rheumatol. 1998;107S:66–67.
    1. Malmgren B, Norgren S. Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol Scand. 2002;60:65–71.
    1. Huber MA. Osteogenesis imperfecta. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:314–320.
    1. Saeves R, Lande Wekre L, et al. Oral findings in adults with osteogenesis imperfecta. Spec Care Dentist. 2009;29:102–108.
    1. Pillion JP, Shapiro J. Audiological findings in osteogenesis imperfecta. J Am Acad Audiol. 2008;19:595–601.
    1. Vincent R, Gratacap B, Oates J, Sperling NM. Stapedotomy in osteogenesis imperfecta: a prospective study of 23 consecutive cases. Otol Neurotol. 2005;26:859–865.
    1. Sainz M, García-Valdecasas J, Ballesteros JM. Surgical options for hearing loss in patients with osteogenesis imperfecta. Acta Otorrinolaringol Esp. 2009;60:126–130.
    1. Garretsen TJ, Cremers CW. Stapes surgery in osteogenesis imperfecta: analysis of postoperative hearing loss. Ann Otol Rhinol Laryngol. 1991;100:120–130.
    1. Rotteveel LJ, Beynon AJ, Mens LH, Snik AF, Mulder JJ, Mylanus EA. Cochlear implantation in 3 patients with osteogenesis imperfecta: imaging, surgery and programming issues. Audiol Neurootol. 2008;13:73–85.
    1. Shapiro JR, Sponsellor PD. Osteogenesis imperfecta: questions and answers. Curr Opin Pediatr. 2009;21:709–716.
    1. Lund AM, Hansen M, Kollerup G, Juul A, Teisner B, Skovby F. Collagen – derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr. 1998;87:1131–1137.
    1. Engelbert RH, Pruijs HE, Beemer FA, Helders P. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil. 1998;79:1590–1594.
    1. Russell DJ, Rosenbaum PL, Avery LM, Lane M. Gross motor function measure (GMFM-66 and GMFM-88) User’s Manual. 1st Edition. London, United: Mac Keith Press; 2002.
    1. Msall ME, DiGaudio K, Duffy LC, LaForest S, Braun S, Granger CV. WeeFIM. Normative sample of an instrument for tracking functional independence in children. Clin Pediatr Phila. 1994;33:431–438.
    1. Bleck EE. Non operative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orth Rel Res. 1981;159:111–122.
    1. Binder H, Conway A, Gerber LH. Rehabilitation approaches to children with osteogenesis imperfecta: a ten-year experience. Arch Phys Med Rehabil. 1993;74:386–390.
    1. Gerber LH, Binder H, Berry R, et al. Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Arch Phys Med Rehab. 1998;79:46–51.
    1. Brunelli PC, Frediani P. Surgical treatment of the deformities of the long bones in severe osteogenesis imperfecta. Ann NY Acad Sci. 1988;543:170–179.
    1. Kocher MS, Shapiro F. Osteogenesis imperfecta. J Am Acad Orthop Surg. 1998;6:225–236.
    1. Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current concepts. Curr Opin Pediatr. 2008;20:52–57.
    1. Gargan MF, Wisbeach A, Fixsen JA. Humeral roding in osteogenesis imperfecta. J Pediatr Orthop. 1996;16:719–722.
    1. Peluso A, Cerullo M. Malignant hyperthermia susceptibility in patients with osteogenesis imperfecta. Paediatr Anaesth. 1995;5:398–399.
    1. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg. 2009;109:1049–1053.
    1. Fraschini P, Maderna P, Cimolin V, Crivellini M, Galli M. Gait analysis and energy consumption evaluation in subjects affected by Osteogenesis Imperfecta. 10th International Conference on Osteogenesis Imperfecta; 2008 Oct 15–18; Ghent, Belgium. 2008.
    1. McHale KA, Tenuta JJ, Tosi LL, McKay DW. Percutaneous intramedullary fixation of long bone deformity in severe osteogenesis imperfecta. Clin Orthop. 1994;305:242–248.
    1. Jerosch J, Mazzotti I, Tomasevic M. Complications after treatment of patients with osteogenesis imperfecta with a Bailey – Dubow rod. Arch Orthop Trauma Surg. 1998;117:240–245.
    1. Zionts LE, Ebramzadeh E, Stott NS. Complications in the use of the Bailey – Dubow extensible nail. Clin Orthop. 1998;348:186–195.
    1. Nicholas RW, James P. Telescoping intramedullary stabilization of the lower extremities for severe osteogenesis imperfecta. J Pediatr Orthop. 1990;10:219–223.
    1. Luhmann SJ, Sheridan JJ, Capelli AM, Schoenecker PL. Management of lower – extremity deformities in osteogenesis imperfecta with extensible intramedullary rod technique: a 20-year experience. J Pediatr Orthop. 1998;18:88–94.
    1. El-Adl G, Khalil MA, Enan A, Mostafa MF, El-Lakkany MR. Telescoping versus non-telescoping rods in the treatment of osteogenesis imperfecta. Acta Orthop Belg. 2009;75:200–208.
    1. Engelbert RH, Helders PJ, Keessen W, Pruijs HEH, Gooskens RHJM. Intramedullary roding in type III osteogenesis imperfecta. Effects on neuromotor development in 10 children. Acta Orthop Scand. 1995;66:361–364.
    1. Gerber LH, Binder H, Berry R, et al. Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Arch Phys Med Rehabil. 1998;79:46–51.
    1. Binder H, Conway A, Hason S, et al. Comprehensive rehabilitation of the child with osteogenesis imperfecta. Am J Med Genet. 1993;45:265–269.
    1. Hanscom DA, Bloom BA. The spine in osteogenesis imperfecta. Orthop Clin North Am. 1988;19:449–458.
    1. Cole WG. Early surgical management of severe forms of osteogenesis imperfecta. Am J Med Genet. 1993;45:270–274.
    1. Topouchian V, Finidori G, Glorion C, Padovani JP, Pouliquen JC. Posterior spinal fusion for kypho – scoliosis associated with osteogenesis imperfecta: long term results. Rev Chir Orthop Reparatrice Appar Mot. 2004;90:525–532.
    1. Wang TG, Yang GF, Alba A. Chronic ventilator use in osteogenesis imperfecta congenita with basilar impression: a case report. Arch Phys Med Rehabil. 1994;75:699–702.
    1. Sawin PD, Menezes AH. Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management. J Neurosurg. 1997;86:950–960.
    1. Janus GJ, Finidori G, Engelbert RH, Pouliquen M, Pruijs JE. Operative treatment of severe scoliosis in osteogenesis imperfecta: results of 20 patients after halo traction and posterior spondylodesis with instrumentation. Eur Spine J. 2000;9:486–491.
    1. Noske DP, van Royen BJ, Bron JL, Vandertop WP. Basilar impression in osteogenesis imperfecta: can it be treated with halotraction and posterior fusion? Acta Neurochir. 2006;148:1301–1305.
    1. Chevrel G, Meunier PJ. Are drugs helpful in adults with osteogenesis imperfecta? Rev Rhum Engl Ed. 1997;64:283–286.
    1. Albright JA. Systemic treatment of osteogenesis imperfecta. Clin Orthop. 1981;159:88–96.
    1. Pedersen U, Charles P, Hansen HH, Elbrønd O. Lack of effects of human calcitonin in osteogenesis imperfecta. Acta Orthop Scand. 1985;56:260–264.
    1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Eng J Med. 2001;344:1434–1441.
    1. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Path. 2002;30:312–321.
    1. Cheng M, Cubert R, Mack S, et al. Osteogenesis imperfecta: pregnancy characteristics, mode of delivery, and neonatal outcome [abstract 0–23]. 7th International Conference on Osteogenesis Imperfecta; 1999 Aug 29–Sep 1; Montreal, Canada. 1999.
    1. Cabral WA, Marini JC. High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet. 2004;74:752–760.
    1. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001;97:1227–1231.
    1. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow – derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999;5:309–313.
    1. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow – derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci. 2002;99:8932–8937.
    1. Horwitz EM, Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit? Cytotherapy. 2008;10:771–774.
    1. Le Blanc K, Gotherstrom C, Ringden O, et al. Fetal mesenchymal stem – cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79:1607–1614.
    1. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119:S150–S162.
    1. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res. 2005;20:1235–1243.
    1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100.
    1. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Safe. 1996;14:158–170.
    1. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine. 1997;76:266–283.
    1. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J. 2003;12:S142–S146.
    1. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;(4):CD005324.
    1. Allgrove J. Biphosphonates. Arch Dis Child. 1997;76:73–75.
    1. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16:360–363.
    1. Huaux JP, Lokietek W. I sAPD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop. 1988;8:71–72.
    1. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate) Eur J Pediatr. 1997;156:792–794.
    1. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo – controlled study. Lancet. 2004;363:1427–1431.
    1. Maasalu K, Haviko T, Martson A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatrica. 2003;92:452–455.
    1. Glorieux FH, Rauch F, Ward LM, et al. Alendronate in the treatment of pediatric osteogenesis imperfecta. J Bone Miner Res. 2004;19:S12.
    1. Williams CJ, Smith RA, Ball RJ, Wilkinson H. Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. Arch Dis Child. 1997;76:169–170.
    1. Shaw NJ. Bisphosphonates in osteogenesis imperfecta. Arch Dis Child. 1997;77:92–93.
    1. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr. 1997;131:622–625.
    1. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr. 1998;157:261–262.
    1. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–952.
    1. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Childhood. 2002;86:356–364.
    1. Cheung MS, Glorieux FH, Rauch F. Intravenous pamidronate in osteogenesis imperfecta type VII. Calcif Tissue Int. 2009;84:203–209.
    1. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long – term therapy. J Clin Endocrinol Metab. 2006;91:511–516.
    1. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006;39:901–906.
    1. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2005;20:758–763.
    1. Antoniazzi F, Zamboni G, Lauriola S, Donadi L, Adami S, Tatò L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr. 2006;149:174–179.
    1. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;(4):CD005088.
    1. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846–1850.
    1. Rauch F, Cornibert S, Cheung M, Glorieux FH. Long – bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40:821–827.
    1. Glorieux FH. Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics. 2007;119:S163–S165.
    1. Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab. 2009;22:55–63.
    1. Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Tatò L. Bone development during GH and GnRH analog treatment. Eur J Endocrinol. 2004;151:S47–S54.
    1. Ernst M, Rodan GA. Increased activity of insulin – like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology. 1990;127:807–814.
    1. McCarthy TL, Centrella M, Canalis E. Regulatory effects of insulin – like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology. 1989;124:301–309.
    1. Hock JM, Centrella M, Canalis E. Insulin – like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology. 1988;122:254–260.
    1. Wergedal JE, Mohan S, Lundy M, Baylink DJ. Skeletal growth factor and other factors known to be present in bone matrix stimulate proliferation and protein synthesis in human bone cells. J Bone Miner Res. 1990;5:179–186.
    1. King D, Jarjoura D, McEwen HA, Askew MJ. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta. J Bone Miner Res. 2005;20:987–993.
    1. King D, Chase J, Havey RM, et al. Effects of growth hormone transgene expression on vertebrae in a mouse model of osteogenesis imperfecta. Spine. 2005;30:1491–1495.
    1. Ohlsson C, Bengtsson B, Isaksson OGP, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocrinol Rev. 1998;19:55–79.
    1. Lund AM, Muller J, Skovby F. Anthropometry of patients with osteogenesis imperfecta. Arch Dis Child. 1999;80:524–528.
    1. Marini JC, Bordenick S, Heavner G, et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab. 1993;76:251–256.
    1. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int. 1992;50:36–41.
    1. Vieira NE, Marini JC, Hopkins E, Abrams SA, Yergey AL. Effect of growth hormone treatment on calcium kinetics in patients with osteogenesis imperfecta type III and IV. Bone. 1999;25:501–505.
    1. Marini JC, Hopkins E, Glorieux FH, et al. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res. 2003;18:237–243.
    1. Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res. 1975;7:488–491.
    1. Marini JC, Hopkins E, Reing CM, et al. Growth hormone treatment trial of children with types III and IV osteogenesis imperfecta. Sixth International Conference on Osteogenesis Imperfecta; 1996 Sep 19–21; Utrecht, The Netherlands.
    1. Sillence D, Briody J, Ault J, et al. Factors which influence the efficacy of growth hormone in 15 children with osteogenesis imperfecta types I and IV. Sixth International Conference on Osteogenesis Imperfecta; 1996 Sep 19–21; Utrecht, The Netherlands. 1996.
    1. Kodama H, Kubota K, Abe T. Osteogenesis imperfecta: are fractures and growth hormone treatment linked? J Pediatr. 1998;132:559–560.
    1. Antoniazzi F, Bertoldo F, Mottes M, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr. 1996;129:432–439.
    1. Marini JC, Gerber NL. Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy. JAMA. 1997;277:746–750.
    1. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem. 1995;64:403–434.
    1. Millington-Ward S, McMahon HP, Farrar GJ. Emerging therapeutic approaches for osteogenesis imperfecta. Trends Mol Med. 2005;11:299–305.
    1. Chamberlain JR, Deyle DR, Schwarze U, et al. Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Mol Ther. 2008;16:187–193.
    1. Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest. 1996;97:448–454.
    1. Grassi G, Forlino A, Marini JC. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutationspecific and shows competitive binding effects. Nucleic Acids Res. 1997;25:3451–3458.
    1. Millington-Ward S, McMahon HP, Allen D, et al. RNAi of COL1A1 in mesenchymal progenitor cells. Eur J Hum Genet. 2004;12:864–866.
    1. Pereira RF, O’Hara MD, Laptev AV, et al. Marrow stromal cells as a source of progenitor cells for non hematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1998;95:1142–1147.
    1. Marini JC. Osteogenesis imperfecta calls for caution. Nat Med. 1999;5:466–467.
    1. Bishop NJ. Osteogenesis imperfecta calls for caution. Nat Med. 1999;5:466–467.
    1. Panaroni C, Gioia R, Lupi A, et al. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood. 2009;114:459–468.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe